| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
RV01 targets multiple pathways. It inhibits DNA damage and reduces ALDH2 mRNA expression induced by ethanol. The compound exhibits hydroxyl radical scavenging activity, indicating antioxidant properties. It decreases iNOS expression, suggesting anti-inflammatory and anti-neuroinflammatory effects. RV01 also reduces tumor necrosis factor-alpha (TNF-α).
|
|---|---|
| ln Vitro |
In vitro, RV01 exhibits hydroxyl radical scavenging activity. It decreases iNOS expression and has anti-neuroinflammatory effects, reducing TNF-α. The compound inhibits DNA damage and reduces ethanol-induced ALDH2 mRNA expression. Its antioxidant and anti-inflammatory properties have been characterized in various cell-based assays, demonstrating potential for research into oxidative stress and neuroinflammation.
|
| ln Vivo |
In vivo, RV01 is used in research on oxidative stress, neuroinflammation, and the molecular mechanisms underlying neurodegenerative and inflammatory diseases. Its antioxidant and anti-inflammatory properties suggest potential therapeutic applications in conditions such as neurodegenerative diseases and inflammatory disorders. Detailed in vivo studies are needed to fully characterize its pharmacological effects.
|
| Enzyme Assay |
For in vitro antioxidant assays, RV01 is evaluated for hydroxyl radical scavenging activity. The compound is incubated with hydroxyl radical-generating systems (e.g., Fenton reaction) and a reporter molecule. Hydroxyl radical scavenging activity is measured by monitoring the decrease in reporter signal. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, RV01 is typically tested on neuronal cells or immune cells. Cells are treated with the compound at various concentrations (typically 1-100 µM) and stimulated with inflammatory stimuli (e.g., LPS) or exposed to oxidative stress. iNOS expression is measured by Western blotting or qPCR. TNF-α and other inflammatory cytokines are measured by ELISA. DNA damage is assessed by comet assay or γ-H2AX staining. ALDH2 mRNA expression is measured by qPCR.
|
| Animal Protocol |
For in vivo animal experiments, RV01 is typically administered orally or intraperitoneally to rodent models of neurodegenerative or inflammatory diseases. The compound is given at doses ranging from 10-100 mg/kg for 1-4 weeks. Behavioral tests are performed to assess neurological function. Brain tissues are collected for histological analysis and biochemical assays. Inflammatory markers and oxidative stress parameters are measured in blood and tissue samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for RV01 are limited. As a small molecule with a molecular weight of 263.29 g/mol and formula C₁₇H₁₃NO₂, it is expected to have moderate oral bioavailability. The compound's resveratrol-like structure suggests it may be metabolized via glucuronidation and sulfation. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for RV01 are limited. As a resveratrol analogue, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human therapeutic use. Standard laboratory safety practices should be followed when handling.
|
| References |
|
| Additional Infomation |
RV01 is a research-use only compound and has not been approved for clinical applications. It is also known as RV-01. Its molecular weight is 263.29, and its formula is C₁₇H₁₃NO₂. The compound is a resveratrol analogue with potent antioxidant and anti-inflammatory properties, used in research on oxidative stress, neuroinflammation, and neurodegenerative diseases. It is available from various research chemical suppliers.
|
| Molecular Formula |
C17H13NO2
|
|---|---|
| Molecular Weight |
263.290624380112
|
| Exact Mass |
263.094
|
| CAS # |
1016897-10-1
|
| PubChem CID |
56837609
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1C=C(C=C(C=1)/C=C/C1C=CN=C2C=CC=CC=12)O
|
| InChi Key |
YRSOXYVELWTHAE-AATRIKPKSA-N
|
| InChi Code |
InChI=1S/C17H13NO2/c19-14-9-12(10-15(20)11-14)5-6-13-7-8-18-17-4-2-1-3-16(13)17/h1-11,19-20H/b6-5+
|
| Chemical Name |
5-[(E)-2-quinolin-4-ylethenyl]benzene-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~18.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7981 mL | 18.9905 mL | 37.9809 mL | |
| 5 mM | 0.7596 mL | 3.7981 mL | 7.5962 mL | |
| 10 mM | 0.3798 mL | 1.8990 mL | 3.7981 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
